He (MAB) was one of the boards biggest pumpers-saying pps would go to $25!

From someone who says they attended annual meeting (and thanks):

By: andre726
21 Jun 2007, 03:40 PM EDT
Msg. 12381 of 12381
Jump to msg. #
Annual meeting

Real quick as I've got much to do during this return trip to the Boston area:

Started out with a recitation of the vote results. Interestingly, votes withheld ranged up to 800,000 for EACH of the directors. Never happened before in my experience. Still, all votes passed with 8 million or so FOR.

Official meeting adjourned. Chairman Little went through a presentation about MFIC. Not bad....perhaps even good....which included the company's alleged objective of being listed on AMEX within twelve months.

Then, questions. I was the only one who asked. There was apparently an investor or two there aside from me...but they remained silent.

First question: operating expenses far too high, sales expense in particular too high. I compared Q1 2006's $3,050,000 and Q1 2007's $2,800,000 revenues and pointed out that Q1 2007's selling expense was $200,000 plus thousand HIGHER despite its revenues being $350,000 LOWER.

Chairman Little pointed out that operating expenses were about the same as Q4 2006 (which, in my opinion, is nothing to brag about since revenues were a whopping $2,240,000 lower) and then asked Dennis Riordan to comment. He then went into his "we already answered that during the conference call and it has to do with adding new salespeople" response.

My response: "Yes. I know that's what you said during the conference call. And as I knew that the conference call was being recorded for prosperity, I didn't pursue the matter any further than I did...."

Suffice to say they had no answer to my question as to how Q1 2007's sales expense was $100,000 higher than Q3 2006 when Q3 2006 was a $3.553 million quarter (i.e., $750,000 higher than Q1 2007), especially since the new salespeople had been hired BEFORE Q3 2006. They had no answer to my question about "are they being paid $300,000 each in base annual salary in light of four new sales resources being paid $300,000 more during a single quarter as compared to Q1 2006 (the lesser Q1 2007 revenues resulting in $97,000 less in commissions being paid out such that the increase in sales expenses was actually closer to $300,000).

Dennis Riordan tried to say something about Q1 2007 actually being a $3.5 million quarter if those $800,000 worth of equipment had been shipped out by the end of Q1 2007. I asked him if any commissions were paid on those sales in that it was my understanding that commissions are paid upon shipment. He acknowledged, "No".

He then said it was something he would look into.

Second question: Japan sales. 2004 average: $625,000 per quarter. Q4 2006: $125,000. Q1 2007: $196,000. Suffice to say that, after hearing the same BS about constant pressure reducing the need for replacement parts (20 years of lab equipment sales involved NO constant pressure and only a handful of constant pressure production machines were sold to Japan since 2005), there was general recognition that there was a serious problem that needed to be looked into immediately as a top priority management exercise.

Third question related to the horrendous inconsistency in the messages delivered on March 29 and April 2.

Chairman Little said that was the last question (I actually had several more) and asked everyone to make their way to the new lab.

I figured that the lab would look very much like a lab....and left to proceed with my day.

So...the Board of Directors have been made aware of some things to be looked into. We'll see if any positive changes occur as a result.

IG was there sitting apart from other Directors. I was not made aware of any new hiring of a new IR person.


(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy)

Will it ever, ever reach .01 again?

lol, I am only going to be patient with SLJB until Nov 2007!

http://www.scientistlive.com/17984/influenza-pandemic-vaccines-spread-them-thin.thtml

MFIC Announces Opening of Microfluidics Technology Center
Innovation Hub Dedicated to Advancing the Micro- and Nano-Formulation Fields
Jun 21, 2007 7:00:00 AM
Copyright Business Wire 2007
NEWTON, Mass.--(BUSINESS WIRE)--

MFIC Corporation (MFIC or the Company)(OTCBB: MFIC) today announced the opening of the Microfluidics Technology Center, a state-of-the-art research and discovery facility located at the MFIC company headquarters in Newton, MA. MFIC is an industry-leader in fluid formulation processing equipment to produce the most uniform and smallest liquid and solid particles available for the biotech, pharmaceutical, chemical, personal care and food industries.

"The Microfluidics Technology Center will house our highly-specialized research team, dedicated to advancing the formulation field by developing new applications for Microfluidics' technology and pursuing groundbreaking work in the field of nanotechnology," said Dr. Thomai Panagiotou, Vice President of Research and Development. "We are very excited about the Center and believe it will serve as an innovation hub, playing a critical role in unlocking countless formulation solutions for our customers--including potentially life-saving drugs--that to date could not be formulated."

The Microfluidics Technology Center will provide customers full access to the Company's R&D engineers and complete product suite to prepare, characterize and optimize formulation samples. Engineers will also assist customers in improving their existing products through reformulation using proprietary, leading-edge, high-shear Microfluidizer(R) materials processors.

"The opening of the Center demonstrates our ongoing commitment to advancing the industry and to providing the highest quality of service to our customers," said Bob Bruno, President and Chief Operating Officer. "While we have always worked closely with customers to solve their most challenging formulation problems, the Microfluidics Technology Center will maximize this experience by providing access to the best engineers and the most advanced equipment in a single-laboratory setting designed specifically with our customers' unique needs in mind."

About MFIC Corporation:

MFIC Corporation, through its Microfluidics Division, designs, manufactures and distributes patented and proprietary high performance Microfluidizer(R) materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries. MFIC applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available, and has provided manufacturing systems for nanoparticle products for more than 15 years.

The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers.

Please fill me in. Is there still a slight delay?

Please be advised that the financials which were promised on November 15 2006 will be
posted shortly. We have experience a slight unforeseeable delay. This delay will be
address by 4am EST and the financials will be posted at that time or shortly after.
A new CEO statement will be posted early on November 16 2006 explaining the delay
and matters concerning the financials. It is our intention to post this statement prior to
posting the financials.
We sincerely apologize if this has caused any problems to our shareholders; it is clearly
not our intention to do so.
Thank you all for your patience, understanding, and continued support.
Petar Vucicevich

I would bet the SEC could be interested in talking to your "dependable source".

Hey ed, I learn from my mistakes. How about you?

Yeah, better get some before Petards next PR or you will be an empty bagholder,lol.

http://www.sciencedaily.com/upi/index.php?feed=Science&article=UPI-1-20070619-14351400-bc-canada....

You are welcome choctaw. Please post as you see fit . It is kind of lonely on this board :)

To Interpol? Remember, you never answered my question to you after 3-4 requests!

>turn myself in<

SREA email spam/scam:

SREA Jumps 25% After News Releases!

Score One Inc.
SREA
$0.25 UP 25%

SREA announced its plan to develop a $75 Million project duplicates a
successful plan in 2006 than returned over $100 million in profits.
Investors are getting in fast. Read the news and get all over SREA
Tuesday

Unigene to Present Initial Animal Data on Site-Directed Bone Growth
Unigene Laboratories, Inc. (OTCBB: UGNE) will present initial animal data for its site-directed bone growth (SDBG) technology on Monday, June 25, 2007 at the 17th Scientific Meeting of the International Bone and Mineral Society in Montreal, Canada.

The poster presentation is entitled “Rapid Site-Specific Bone Growth by a Combination of Bone Marrow Ablation and Anabolic Therapy,” and will demonstrate the technology’s ability to create new bone within the femur of an animal and thereby improve the biomechanical properties of the bone.

“We believe that SDBG has the potential to decrease cost and improve the quality of life of patients with certain bone conditions,” commented Dr. Warren Levy, President and CEO of Unigene. “Our team of researchers at Unigene and Yale, in collaboration with leading clinicians in interventional radiology and orthopedic surgery at Johns Hopkins Medical School, is actively exploring the capabilities of the technology. We will seek to complement our activities with those of a development partner having experience with products that combine biological agents and devices.”

About SDBG

The SDBG technology was developed by scientists at Unigene and Yale University Medical School. It involves a minimally invasive surgical procedure in conjunction with a proprietary device and the administration of one or more biological agents, including a systemic anabolic agent. Additional animal studies are underway and human studies are planned in the near future.

The technology may find utility in the treatment and/or prevention of vertebral compression, hip and long bone fractures, and chronic back pain.

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical®, Unigene’s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical® to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene’s patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene’s patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call (973) 882-0860 or visit www.unigene.com. For information about Fortical, visit www.fortical.com.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based upon Unigene Laboratories, Inc.’s management’s current expectations, estimates, beliefs, assumptions, and projections about Unigene’s business and industry. Words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “potential,” “continue,” and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These risks and uncertainties include the risks associated with the effect of changing economic conditions, trends in the products markets, variations in Unigene's cash flow, market acceptance risks, technical development risks and other risk factors detailed in Unigene's Securities and Exchange Commission filings.

Unigene Investors:
The Investor Relations Group
Daniel Berg/Dian Griesel, Ph.D., 212-825-3210
or
Media:
Janet Vazquez, 212-825-3210



Source: Business Wire (June 18, 2007 - 7:30 AM EDT)

Unigene to Present Initial Animal Data on Site-Directed Bone Growth
Unigene Laboratories, Inc. (OTCBB: UGNE) will present initial animal data for its site-directed bone growth (SDBG) technology on Monday, June 25, 2007 at the 17th Scientific Meeting of the International Bone and Mineral Society in Montreal, Canada.

The poster presentation is entitled “Rapid Site-Specific Bone Growth by a Combination of Bone Marrow Ablation and Anabolic Therapy,” and will demonstrate the technology’s ability to create new bone within the femur of an animal and thereby improve the biomechanical properties of the bone.

“We believe that SDBG has the potential to decrease cost and improve the quality of life of patients with certain bone conditions,” commented Dr. Warren Levy, President and CEO of Unigene. “Our team of researchers at Unigene and Yale, in collaboration with leading clinicians in interventional radiology and orthopedic surgery at Johns Hopkins Medical School, is actively exploring the capabilities of the technology. We will seek to complement our activities with those of a development partner having experience with products that combine biological agents and devices.”

About SDBG

The SDBG technology was developed by scientists at Unigene and Yale University Medical School. It involves a minimally invasive surgical procedure in conjunction with a proprietary device and the administration of one or more biological agents, including a systemic anabolic agent. Additional animal studies are underway and human studies are planned in the near future.

The technology may find utility in the treatment and/or prevention of vertebral compression, hip and long bone fractures, and chronic back pain.

About Unigene

Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical®, Unigene’s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical® to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene’s patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene’s patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call (973) 882-0860 or visit www.unigene.com. For information about Fortical, visit www.fortical.com.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based upon Unigene Laboratories, Inc.’s management’s current expectations, estimates, beliefs, assumptions, and projections about Unigene’s business and industry. Words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “potential,” “continue,” and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These risks and uncertainties include the risks associated with the effect of changing economic conditions, trends in the products markets, variations in Unigene's cash flow, market acceptance risks, technical development risks and other risk factors detailed in Unigene's Securities and Exchange Commission filings.

Unigene Investors:
The Investor Relations Group
Daniel Berg/Dian Griesel, Ph.D., 212-825-3210
or
Media:
Janet Vazquez, 212-825-3210



Source: Business Wire (June 18, 2007 - 7:30 AM EDT)

Meeting news from another board:

By: billypancake
18 Jun 2007, 09:02 AM EDT
Msg. 13539 of 13556
Jump to msg. #
Notes from the meeting. 1.) The gentelman from Winslow Management said to Warren Levy, basically, you [UGNE] are talking about a potential billion drug in pth, great potential in an oa indication for calcitonin, new peptides, SDBG, etc., but the stock price is going nowhere, does UGNE have the management team in place to take this company to the next level. The question was almost a direct challenge to this historically family run public corporation. Warren stood his ground and said, essentially, that UGNE creates the peptides, the delivery systems, the science. When/if approved GSK and NVS will handle the business end of the billion dollar drugs and UGNE gets royalties. Actually, it seemed very logical to me at the meeting. Also, the gentelman from Winslow Management and Warren Levy clearly had been talking about the concern raised prior to the meeting. So, I didn't see the Winslow question as a negative at all. 2.) With PTH, Warren said that since UGNE knows much more about the oral delivery of peptides, UGNE "took the bull by the horns." The formulation for PTH has been finalized, the patents filed. A meeting with GSK is in the process of being scheduled. No guarantees, but Warren was comfortable that the project will move forward from here. 2.) The SDBG will involve a needle injection of the biologicals in a procedure at a doctor's office. 3.) Bill S. responded to a question about cash on hand and the $20 million burn rate and said that they hope/expect/feel comfortable [don't remeber the exact word he used] with Fortical revenues covering the burn rate, i.e, new financing was not even an issue at the meeting. 4.) Tid bits, Fortical is 30-35% cheaper than Miacalcin, PTH is only prescribed for 2 years and needs to be cycled. Likely can't be cycled with Fosomax, but can w/ sct., the NVS oa trials will be 2 years, partnership for oral sct still very much in the works. Overall, business UGNE in the best shape it has ever been in.

Thanks to those who answered. Clears up a few questions I had.

I wouldn't be surprised if the SEC was looking into this stock?

or rebelgirl!

rebelgirl, we continue to wait for your reply to this post.

I have been gone for several days and now look at hundreds of PBLS posts. Can anyone point me to a post or 2 which summarize what is happening to pps. TIA.

BCRX presents Phase I flu study:

http://www.investorshub.com/boards/read_msg.asp?message_id=20571729

BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
11:40a ET June 18, 2007 (PR NewsWire)
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) presented results from two Phase I clinical studies of an intramuscular (i.m.) formulation of peramivir at the Options for the Control of Influenza Conference in Toronto, Ontario, Canada. This major international influenza conference is held only once every four years.

These studies represent an important component of the company's clinical development program for peramivir, a neuraminidase inhibitor being developed for the treatment of seasonal and potentially life-threatening influenza. Top-line data are summarized as follows:

-- A total of 51 healthy adult volunteers received either one of three dose regimens of peramivir or placebo -- Maximum plasma concentrations of peramivir (ranging from approximately 4,000 ng/mL to 15,000 ng/mL) were present as early as 20 minutes after administration -- Peramivir exhibited a long terminal half-life (17.7 to 24.3 hours) -- The bioavailability of single doses of i.m. peramivir is high (>98%) -- Peramivir was well-tolerated in both of these studies

Jon P. Stonehouse, Chief Executive Officer of BioCryst said "these findings suggest an excellent safety profile of peramivir when given as an intramuscular injection, and, secondly, the concentrations of peramivir in blood after intramuscular dosing are reassuringly high and are similar to levels after intravenous administration. We look forward to the completion of our ongoing Phase II study of i.m. peramivir in the treatment of acute influenza in outpatients."

BioCryst is advancing the clinical development of peramivir under terms of a contract from the U.S. Department of Health and Human Services (DHHS) which on January 4, 2007 awarded BioCryst a $102.6 million, four-year contract to develop peramivir for the treatment of seasonal and life-threatening influenza. Funding from the contract will support Phase II and Phase III product development activities including manufacturing of clinical lots, process validation, clinical studies and other product approval requirements needed for U.S. licensure. BioCryst retains 100% development and commercialization rights to peramivir worldwide other than in Japan and Korea where BioCryst recently established strategic partnerships with Shionogi & Co. in Japan, and Green Cross in Korea.

About Peramivir

Peramivir is a member of the class of antiviral agents that inhibit influenza viral neuraminidase, an enzyme that is essential for the spread of influenza virus within the host. Peramivir is an inhibitor of influenza A and B neuraminidases and certain strains of influenza viruses that may be resistant to available neuraminidase inhibitors but are susceptible to peramivir in laboratory tests. At the 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy in September, 2006, data were presented showing that injectable formulations of peramivir were safely administered to healthy subjects at daily doses up to approximately 600 mg. At the same meeting, animal data were presented showing peramivir promoted survival in animals infected with highly pathogenic strains of the H5N1 virus. Peramivir injection has received Fast Track designation from US FDA and the availability of an intravenous neuraminidase inhibitor may be important in treating patients hospitalized with severe and potentially life-threatening influenza. The availability of an intramuscular formulation of peramivir could ensure appropriate dosing which may be a concern with currently available oral or inhaled anti-influenza agents.

About Influenza

The influenza virus causes an acute viral disease of the respiratory tract. Unlike the common cold and some other respiratory infections, seasonal flu can cause severe illness, resulting in life-threatening complications. According to the Centers for Disease Control and Prevention, every year in the United States more than 200,000 people are hospitalized from flu complications, and about 36,000 people die from flu. Most at risk are young children, the elderly, and people with seriously compromised immune systems.

Avian influenza A viruses of H5N1 subtype are circulating among birds worldwide, the virus is considered extremely contagious in fowl. It is believed that all species of birds are susceptible to avian influenza, but domestic poultry, including chickens and turkeys, are among the more susceptible to the highly pathogenic strain. According to the World Health Organization, at least 261 people have contracted H5N1 avian influenza, of which at least 157 have died. Almost all of these infections are believed to have resulted from contact with infected poultry.

About BioCryst

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine(TM) in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life- threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization of BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine(TM) in markets across Europe, Asia, Australia and certain neighboring countries. In January, 2007 the U.S. Department of Health and Human Services (DHHS) awarded a $102.6 million, four-year contract to BioCryst for advanced development of peramivir to treat seasonal and life-threatening influenza. In February, 2007 BioCryst established a partnership with Shionogi & Co., to develop and commercialize peramivir in Japan. For more information about BioCryst, please visit the company's web site at http://www.biocryst.com.

Forward-looking statements

This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that the favorable results of peramivir in animals may not be replicated in humans, the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization of Fodosine(TM) in both T-ALL and CTCL may not be successful, that we may not resolve satisfactorily the particulate matter issue with the intravenous formulation of Fodosine(TM), that we may not obtain a satisfactory SPA for Fodosine(TM) for treatment of CTCL promptly or at all, that DHHS could reduce or eliminate funding for peramivir, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future clinical trials may not have positive results, that we may not be able to complete successfully the Phase IIb trial for Fodosine(TM) that is currently planned to be pivotal, that we may not be able to commence the proposed Phase III trial for peramivir within the time frame we currently expect or at all, that we may not be able to announce preclinical developments for additional compounds by year-end 2007 as currently proposed, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not reach favorable agreements with potential pharmaceutical and biotech partners for further development of its product candidates, that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, current reports on Form 8-K which identify important factors that could cause the actual results to differ materially from those contained in the projections or forward-looking statements.

SOURCE BioCryst Pharmaceuticals, Inc.

Jonathan M. Nugent, V.P. Corporate Communications of BioCryst Pharmaceuticals, Inc., +1-205-444-4633, jnugent@biocryst.com
http://www.biocryst.com

Oh yeah, how about showing us your "information" sources. Or would you be one who believed all the past PR's from Sulja?

UGNE news:

http://www.investorshub.com/boards/read_msg.asp?message_id=20381822

UGNE news (repost from bad link)

http://www.investorshub.com/boards/read_msg.asp?message_id=20381822

Any news from the meeting?

UGNE news:

http://www.investorshub.com/boards/post_info.asp

SEC Votes To End Short-Selling 'Grandfather' Protections

June 13, 2007 11:23 ET
By Judith Burns
Of DOW JONES NEWSWIRES

WASHINGTON (Dow Jones)--The Securities and Exchange Commission voted Wednesday to
approve a change to tighten rules intended to curb manipulative short sales,
including so-called "naked" short sales.

The change eliminates a controversial exception that shielded existing short
positions from requirements to deliver hard-to-borrow shares within 13 days of
settlement. Once the change takes effect, short positions previously protected by
the grandfather clause must be closed out within 35 days.

SEC Chairman Christopher Cox said persistent failures to deliver shares sold
short seem to be due to the grandfather protections, which the SEC included in
2004 to prevent stock-market volatility. Critics complained the protections
undermined efforts to clean up abuses involving "naked" short sales.

Short selling involves sales of borrowed securities, producing profits when
prices decline. The practice is legal, but the SEC's Regulation SHO sought to
prevent "naked" short sales, in which short sellers don't borrow securities they
sell.

SEC officials said delivery failures have declined about 35% overall since
Regulation SHO took effect and have fallen about 53% for hard-to-borrow stocks
defined as "threshold" securities.

-By Judith Burns, Dow Jones Newswires, 202-862-6692; Judith.Burns@dowjones.com
(END) Dow Jones Newswires

Most anti-americans don't hold the same values as we do!

May be a hoax but I like it :)


Actual letter from an Iowa resident and sent to his senator)

The Honorable Tom Harkin
731 Hart Senate Office Building
Phone (202) 224 3254
Washington DC , 20510

Dear Senator Harkin,

As a native Iowan and excellent customer of the Internal Revenue Service, I am
writing to ask for your assistance. I have contacted the Department of Homeland
Security in an effort to determine the process for becoming an illegal alien and
they referred me to you.

My primary reason for wishing to change my status from U.S. Citizen to illegal
alien stems from the bill which was recently passed by the Senate and for which
you voted. If my understanding of this bill's provisions is accurate, as an
illegal alien who has been in theUnited States for five years, all I need to do to
become a citizen is to pay a $2,000 fine and income taxes for three of the last
five years. I know a good deal when I see one and I am anxious to get the process
started before everyone figures it out.



Simply put, those of us who have been here legally have had to pay taxes every
year so I'm excited about the prospect of avoiding two years of taxes in return
for paying a $2,000 fine. Is there any way that I can apply to be illegal
retroactively? This would yield an excellent result for me and my family because
we paid heavy taxes in 2004 and 2005.

Additionally, as an illegal alien I could begin using the local emergency room as
my primary health care provider. Once I have stopped paying premiums for medical
insurance, my accountant figures I could save almost $10,000 a year.

Another benefit in gaining illegal status would be that my daughter would receive
preferential treatment relative to her law school applications, as well as
"in-state" tuition rates for many colleges throughout the United States for my
son.

Lastly, I understand that illegal status would relieve me of the burden of
renewing my driver's license and making those burdensome car insurance premiums.
This is very important to me given that I still have college age children driving
my car.

If you would provide me with an outline of the process to become illegal
(retroactively if possible) and copies of the necessary forms, I would be most
appreciative.

Thank you for your assistance.

Your Loyal Constituent,
Donald Ruppert
Burlington , IA

IPS to Integrate MedeFile Electronic Medical Records Management Solution Into Managed Services Platform

ORLANDO, Fla. and CEDAR KNOLLS, N.J., June 13, 2007 /PRNewswire-FirstCall via COMTEX/ -- Integrated Pain Solutions, LLC (IPS), a wholly owned subsidiary of PainCare Holdings, Inc. (PRZ), and MedeFile International, Inc. (OTC Bulletin Board: MDFI), a leader in portable electronic medical records management, today announced that the Companies have agreed to collaborate on the integration of MedeFile's electronic medical record management solutions into IPS' managed services offerings, providing for a value-added enhancement for medical insurers, workers compensation carriers and self-insured trade unions and employer groups, to mention a few.

Maria R. McAfee, President of IPS, noted, "MedeFile offers a very robust and user-friendly solution for consolidating and managing personal health and medical records in a convenient web-enabled environment. By integrating this offering into our managed services platform, we believe we will succeed in further differentiating the total IPS solution and provide the tangible means for payors to extend enhanced benefits, control and value to their respective members."

"MedeFile was founded on the belief that empowering patients with the ability to maintain control over all of their medical and health information across all providers and across time will have a cascading, positive effect on improving the overall healthcare system and the universal quality of care, while generating savings for payors due to the reduction or elimination of duplicate procedures and tests and avoidance of costly medical errors. In this regard, we are very pleased that IPS has selected the MedeFile solution to be offered as part of its comprehensive managed service platform being marketed to large payors," stated Milton Hauser, Chairman and CEO of MedeFile International, Inc.

Established to serve major medical insurers, workers compensation carriers and large self-insured trade unions and employer groups, IPS is the nation's first and foremost pain-focused managed services organization that is dedicated to achieving value-based, cost-saving and patient-centric care through a multi-disciplinary network of highly privileged providers and specialists; its proprietary, evidenced-based clinical pathways for the treatment of acute and chronic musculoskeletal pain; a novel IT platform used to capture, track, analyze and report outcome data; and a fully-integrated support and service platform to provide telephonic and electronic utilization management, case management and care coaching services.

About Integrated Pain Solutions (IPS)

Integrated Pain Solutions (IPS), a wholly-owned subsidiary of PainCare Holdings, Inc., is the first and only managed services organization offering a multidisciplinary healthcare network focused on pain management to payor organizations, such as insurance and workers' compensation carriers and unions. IPS reduces costs and increases quality of life by providing highly credentialed physicians and centers of excellence on pay-for-performance incentives, a continuum of care that begins with care coaching, a shared financial and clinical data warehouse, and evidence-based clinical outcome measurements to determine the most effective pain-management plan. For more information, please visit .

About PainCare Holdings, Inc.

Headquartered in Orlando, Florida, PainCare Holdings, Inc. is one of the nation's leading providers of pain-focused medical and surgical solutions and services. Through its proprietary network of acquired or managed physician practices and ambulatory surgery centers, and in partnership with independent physician practices and medical institutions throughout the United States and Canada, PainCare is committed to utilizing the most advanced science and technologies to diagnose and treat pain stemming from neurological and musculoskeletal conditions and disorders.

Through its wholly owned subsidiary, Caperian, Inc., PainCare offers medical real estate and development services. Through Integrated Pain Solutions, the Company is engaged in pioneering the nation's first Managed Services Organization that offers a multi-disciplinary healthcare network focused on the treatment of pain. For more information on PainCare Holdings, please visit .

About MedeFile International, Inc

MedeFile has developed a proprietary system for gathering and digitizing medical records so that individuals can have a comprehensive record of all of their medical visits. MedeFile's primary product is the MedeFile system, a highly secure system for gathering and maintaining medical records. The MedeFile system is designed to gather all of its members' actual medical records and create a single, comprehensive medical record that is accessible 24 hours a day, seven days a week.

Representing an advanced, yet easy-to-use, approach to portable, electronic medical records management, MedeFile combines state-of-the-art technology and the Internet to make medical data instantly accessible to each MedeFile subscriber and his or her authorized healthcare providers from anywhere in the world. In addition to accessing one's medical records through MedeFile's secure Internet portal found at , members can carry their entire medical history and emergency information wherever they go on a unique device called a MedeDrive - a proprietary USB drive designed to be carried on a keychain. The MedeDrive plugs into any USB port of a Windows- based PC; and because MedeDrive automatically loads its own viewer, users do not require any special programs or software to view data. MedeMobile provides on-the-go subscribers with the ability to enjoy even greater flexibility and access to their personal health information wherever and whenever they need it.

For more information about MedeFile and the MedeFile system, visit .

PainCare's Safe Harbor Statement

This press release contains forward-looking statements that may be subject to various risks and uncertainties. Such forward-looking statements are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are made based on management's current expectations or beliefs as well as assumptions made by, and information currently available to, management. These forward-looking statements, which may include statements regarding our future financial performance or results of operations, including expected revenue growth, cash flow growth, future expenses, future operating margins and other future or expected performance, are subject to the following risks: the acquisition of businesses or the launch of new lines of business, which could increase operating expenses and dilute operating margins; the inability to attract new patients by our owned practices, the managed practices and the limited management practice; increased competition, which could lead to negative pressure on our pricing and the need for increased marketing; the inability to maintain, establish or renew relationships with physician practices, whether due to competition or other factors; the inability to comply with regulatory requirements governing our owned practices, the managed practices and the limited management practices; that projected operating efficiencies will not be achieved due to implementation difficulties or contractual spending commitments that cannot be reduced; and to the general risks associated with our businesses.

In addition to the risks and uncertainties discussed above you can find additional information concerning risks and uncertainties that would cause actual results to differ materially from those projected or suggested in the forward-looking statements in the reports that we have filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release represent our judgment as of the date of this release and you should not unduly rely on such statements. Unless otherwise required by law, we undertake no obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise after the date of this press release. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in the filing may not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements

MedeFile International's Safe Harbor Statement

With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of MedeFile could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the Company's operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rates, and unanticipated events such as terrorist activities. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, and such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. For further risk factors associated with our Company, review our SEC filings.

FOR MORE INFORMATION, PLEASE CONTACT: Media Relations Suzanne Beranek, APR, Beranek Communications, LLC 407-475-0763 or via email at suzanne@beranekcommunications.com FOR MORE INFORMATION, PLEASE CONTACT: Dodi Handy, President and CEO, or Daniel Conway, Chief Strategist Elite Financial Communications Group 407-585-1080 or via email at prz@efcg.netSOURCE PainCare Holdings, Inc.
Suzanne Beranek, APR, Media Relations of Beranek Communications, LLC,+1-407-475-0763, suzanne@beranekcommunications.com, Dodi Handy, President and CEO,Daniel Conway, Chief Strategist, both of Elite Financial Communications Group,+1-407-585-1080, prz@efcg.net

both of em,lol

Place me on list-thanks.

AM I a Bad American By George Carlin:



I Am Your Worst Nightmare. I am a BAD American. I am George Carlin.

I believe the money I make belongs to me and my family, not some mid level governmental functionary be it Democratic or Republican!

I'm in touch with my feelings and I like it that way!

I think owning a gun doesn't make you a killer, it makes you a smart American.


I think being a minority does not make you noble or victimized, and does not entitle you to anything.

I believe that if you are selling me a Big Mac, do it in English.


I believe everyone has a right to pray to his or her God when and where they want to.


My heroes are John Wayne, Babe Ruth, Roy Rogers, and whoever canceled Jerry Springer.

I don't hate the rich. I don't pity the poor.


I know wrestling is fake and I don't waste my time watching or arguing about it.


I've never owned a slave, or was a slave, I haven't burned any witches or been persecuted by the Turks and neither have you! So, shut up already.

I believe if you don't like the way things are here, go back to where you came from and change your own country! This is AMERICA.


I want to know which church is it exactly where the Reverend Jesse Jackson preaches, where he gets his money, and why he is always part of the problem and not the solution. Can I get an AMEN on that one?



I think the cops have every right to shoot your sorry rear if you're running from them..


I also think they have the right to pull you over if you're breaking the law, regardless of what color you are.

And, no, I don't mind having my face shown on my drivers license. I think it's good..... and I'm proud that "God" is written on my money.

I think if you are too stupid to know how a ballot works, I don't want you deciding who should be running the most powerful nation in the world for the next four years.

I dislike those people standing in the intersections trying to sell me stuff or trying to guilt me into making "donations" to their cause.


I believe that it doesn't take a village to raise a child, it takes two parents.


And what is going on with gas prices... again?


I believe "illegal" is illegal no matter what the lawyers think.

I believe the American flag should be the only one allowed in AMERICA!


If this makes me a BAD American, then yes, I'm a BAD

If you don't like America-get the *&^% out!

AM I a Bad American By George Carlin:


I Am Your Worst Nightmare. I am a BAD American. I am George Carlin.

I believe the money I make belongs to me and my family, not some mid level governmental functionary be it Democratic or Republican!

I'm in touch with my feelings and I like it that way!

I think owning a gun doesn't make you a killer, it makes you a smart American.


I think being a minority does not make you noble or victimized, and does not entitle you to anything.

I believe that if you are selling me a Big Mac, do it in English.


I believe everyone has a right to pray to his or her God when and where they want to.


My heroes are John Wayne, Babe Ruth, Roy Rogers, and whoever canceled Jerry Springer.

I don't hate the rich. I don't pity the poor.


I know wrestling is fake and I don't waste my time watching or arguing about it.


I've never owned a slave, or was a slave, I haven't burned any witches or been persecuted by the Turks and neither have you! So, shut up already.

I believe if you don't like the way things are here, go back to where you came from and change your own country! This is AMERICA.


I want to know which church is it exactly where the Reverend Jesse Jackson preaches, where he gets his money, and why he is always part of the problem and not the solution. Can I get an AMEN on that one?



I think the cops have every right to shoot your sorry rear if you're running from them..


I also think they have the right to pull you over if you're breaking the law, regardless of what color you are.

And, no, I don't mind having my face shown on my drivers license. I think it's good..... and I'm proud that "God" is written on my money.

I think if you are too stupid to know how a ballot works, I don't want you deciding who should be running the most powerful nation in the world for the next four years.

I dislike those people standing in the intersections trying to sell me stuff or trying to guilt me into making "donations" to their cause.


I believe that it doesn't take a village to raise a child, it takes two parents.


And what is going on with gas prices... again?


I believe "illegal" is illegal no matter what the lawyers think.

I believe the American flag should be the only one allowed in AMERICA!


If this makes me a BAD American, then yes, I'm a BAD

This HAS to be a hoax-got in email. Can anyone with an 8th grade education be this dumb???




>
>Since becoming Speaker of the House of
>Representatives, Nancy Pelosi has weighed in on
>several different topics. After hearing what she has
>said, it is hard for me to believe that there are
>American citizens who actually support her theories
>and can make any sense at all from what she spins.
>Take a good hard look at what she wants. Take special
>note of her last quote.
>
>Insanity Personified: Nancy Pelosi
>
>When questioned about recent stock market highs she
>responded "Only the rich benefit from these record
>highs. Working Americans, welfare recipients, the
>unemployed and minorities are not sharing in these
>obscene record highs."
>
>"There is no question these windfall profits and
>income created by the Bush Administration need to be
>taxed at a 100% rate and those dollars redistributed
>to the poor and working class."
>
>When asked how these new tax dollars would be spent,
>she replied, "We need to raise the standard of living
>of our poor, unemployed and minorities. For example,
>we have an estimated 12 million illegal immigrants in
>our country who need our help along with millions of
>unemployed minorities. Stock market windfall profits
>taxes could go a long ways to guarantee these people
>the standard of living they would like to have as
>'Americans'."
>
>If any of you have studied Economics, you are
>undoubtedly familiar to the philosophy of Karl Marx
>and Friedrich Engels. Together, in 1848, they wrote
>and published the infamous "Communist Manifesto," an
>idealistic vision of the future that has taken root in
>some areas of the world but has always been met with
>failure. From her remarks, Ms Pelosi (and all who
>think like her!) is undoubtedly a Marxist pedagogue,
>and should be regarded with a great deal of concern,
>if not contempt, by all true Americans and proponents
>of the capitalistic free enterprise system - the only
>successful economic system in all of recorded history!
> Please help protect the legacy given to us by our
>forefathers, please promote and honor the sovereignty
>of our great nation, and please thank God that we are
>blessed with both!
>

My chart shows 1000 shares as last buy-a whole $16 worth. Probably cost them $12 to paint,lol.

Yep, someone painted the SLJB tape again. The SEC does not like "painters".

Novartis/UGNE

http://www.investorshub.com/boards/read_msg.asp?message_id=20381822